Zentalis (ZNTL) director Enoch Kariuki granted 57,100 restricted stock units
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kariuki Enoch reported acquisition or exercise transactions in this Form 4 filing.
Zentalis Pharmaceuticals director Enoch Kariuki received an equity award in the form of restricted stock units. The grant covers 57,100 RSUs, each representing one share of common stock at no purchase price. After this award, he directly holds 194,465 shares. The RSUs vest on the earlier of June 16, 2027 or the next annual stockholder meeting, if he continues serving on the board.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Kariuki Enoch
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 57,100 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 194,465 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
RSUs granted: 57,100 units
Grant price: $0.00 per unit
Total holdings after grant: 194,465 shares
+1 more
4 metrics
RSUs granted
57,100 units
Restricted stock units granted on June 16, 2026
Grant price
$0.00 per unit
Price per restricted stock unit in director award
Total holdings after grant
194,465 shares
Common stock directly held following the transaction
RSU vesting date
June 16, 2027
Vests on earlier of this date or next annual meeting
Key Terms
restricted stock units, Non-Employee Director Compensation Program, vest, annual meeting of the Issuer's stockholders
4 terms
restricted stock units financial
"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Non-Employee Director Compensation Program financial
"granted pursuant to the Issuer's Non-Employee Director Compensation Program"
vest financial
"which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual meeting of the Issuer's stockholders financial
"the next occurring annual meeting of the Issuer's stockholders"
FAQ
What insider transaction did Zentalis (ZNTL) director Enoch Kariuki report?
Director Enoch Kariuki reported receiving 57,100 restricted stock units as an equity award. Each RSU represents one share of Zentalis common stock, granted at no purchase price, under the company’s Non-Employee Director Compensation Program.
What are the vesting terms of the Zentalis (ZNTL) RSUs granted to Enoch Kariuki?
The 57,100 restricted stock units vest on the earlier of June 16, 2027 or the next annual stockholder meeting. Vesting is conditioned on Kariuki’s continued service on Zentalis’ board of directors through the applicable vesting date under the compensation program.
What does a grant of restricted stock units mean for Zentalis (ZNTL) insiders?
A restricted stock unit grant gives an insider a right to receive company shares in the future, subject to vesting. For Zentalis, these RSUs align director compensation with shareholder interests by tying value to the company’s stock performance over time until vesting.
Was the Zentalis (ZNTL) insider transaction a market purchase or sale?
The transaction was an equity award, not a market trade. Zentalis granted Enoch Kariuki 57,100 restricted stock units at a price of $0.00 per unit as part of its Non-Employee Director Compensation Program, rather than through open-market buying or selling.